Enzyme:CYP2D6: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
MDElliottMD (talk | contribs) m MDElliottMD moved page Pharmacopedia:Pharmacogenomics sandbox/Enzyme CYP2D6 to Enzyme:CYP2D6: Migrate enzyme entity pages from Pharmacogenomics sandbox to the new Enzyme: namespace |
MDElliottMD (talk | contribs) Add scope="col" to the data-table column headers for screen-reader association (ADA audit M5; designer-claude 2026-05-22) |
||
| Line 8: | Line 8: | ||
{| class="wikitable sortable mw-collapsible mw-collapsed" style="width:100%;" | {| class="wikitable sortable mw-collapsible mw-collapsed" style="width:100%;" | ||
|+ style="white-space:nowrap; text-align:left;" | near-complete CYP2D6 substrate table (click to expand) | |+ style="white-space:nowrap; text-align:left;" | near-complete CYP2D6 substrate table (click to expand) | ||
! Substrate !! Therapeutic class !! CYP2D6 contribution !! Clinical notes | ! scope="col" | Substrate !! scope="col" | Therapeutic class !! scope="col" | CYP2D6 contribution !! scope="col" | Clinical notes | ||
|- | |- | ||
| [[Amitriptyline]] || Tricyclic antidepressant || major || CPIC TCA guideline dose adjustment in CYP2D6 PM/UM. | | [[Amitriptyline]] || Tricyclic antidepressant || major || CPIC TCA guideline dose adjustment in CYP2D6 PM/UM. | ||
| Line 107: | Line 107: | ||
{| class="wikitable" | {| class="wikitable" | ||
! Phenotype !! Abbreviation !! Activity score !! Frequency (varies by ancestry) | ! scope="col" | Phenotype !! scope="col" | Abbreviation !! scope="col" | Activity score !! scope="col" | Frequency (varies by ancestry) | ||
|- | |- | ||
| [[Phenotype:CYP2D6 poor metabolizer|Poor metabolizer]] || PM || 0 || 5–10% (European), 1–2% (East Asian), 3–8% (African) | | [[Phenotype:CYP2D6 poor metabolizer|Poor metabolizer]] || PM || 0 || 5–10% (European), 1–2% (East Asian), 3–8% (African) | ||